Wheeler Bio Launches Redesigned Website Showcasing Expanded Integrated CDMO Capabilities and AI/ML-Enabled ModularCMC™ Platform
核心洞察
Wheeler Bio (搜索), an Oklahoma-based CDMO, has launched a redesigned website reflecting its evolution into a fully integrated biologics development and manufacturing organization spanning from gene to cGMP manufacturing.
The new site highlights the company's AI/ML-enabled ModularCMC™ platform, which combines standardized work packages, Quality-by-Design principles, and AI/ML-informed process development to streamline CMC execution for antibody-based therapeutics.
The platform supports a range of modalities including mAbs, multispecifics (搜索), Fc-fusion proteins (搜索), and antibody-drug conjugates (搜索), ultimately delivering a cGMP product with a comprehensive CTD Module 3 for IND applications.
Wheeler Bio (搜索), an Oklahoma-based Contract Development and Manufacturing Organization specializing in antibody-based therapeutics, announced on June 23, 2026 the launch of its redesigned website, showcasing the company's expanded development and manufacturing capabilities that now serve biologics developers from genes through cGMP manufacturing.
The new digital presence reflects Wheeler Bio (搜索)'s evolution into a fully integrated CDMO, supporting programs from cell line development through cGMP Drug Substance and Drug Product manufacturing. The site is designed to provide a clearer view of the company's broader biologics expertise, manufacturing facilities, service offerings, and preferred partner network.
"As Wheeler Bio (搜索) continues to grow, it was important that our digital presence reflect the full breadth of capabilities, expertise, and capacity we bring to our clients," said Sheli Streck, Chief Commercial Officer, Wheeler Bio. "Our new website showcases the integrated services and scientific depth that support our partners from discovery through cGMP manufacturing, while reinforcing the values that define every engagement: integrity, scientific excellence, transparency, and the high-touch project management approach that sets Wheeler Bio apart."
ModularCMC™ Platform: AI/ML-Enabled Development
Central to the updated website is Wheeler Bio (搜索)'s AI/ML-enabled ModularCMC™ platform, a structured, phase-appropriate approach to antibody-based development. The platform combines standardized work packages, Quality-by-Design principles, and AI/ML-informed process development strategies. By aligning development strategy with regulatory expectations and program objectives, ModularCMC™ helps sponsors streamline CMC execution and reduce development timelines for antibody-based therapeutics.
The platform supports a broad range of modalities, including monoclonal antibodies (搜索) (mAbs), multispecifics (搜索), Fc-fusion proteins (搜索), and antibody-drug conjugates (搜索) (ADCs). ModularCMC™ streamlines the path from drug discovery to cGMP manufacturing through well-defined, systematic work packages, ultimately resulting in a cGMP product supported by a comprehensive Common Technical Document (CTD) Module 3 for Investigational New Drug Applications (INDs).
High-Science, High-Touch Partnership Model
In addition to the ModularCMC platform, the website describes Wheeler Bio (搜索)'s "high-science, high-touch" approach to client partnerships. This model pairs deep scientific expertise with accessible project leadership and timely, transparent communication. The company's mission, as stated on the site, is to accelerate the translation of drug discoveries into clinical impact for partners and the patients they seek to serve.
The redesigned website features enhanced navigation, expanded technical content, updated service descriptions, and new resources to help biotechnology companies evaluate development and manufacturing strategies available at Wheeler Bio (搜索). The company's commitment to timeline transparency, scientific rigor, and a true partnering mindset underpins its positioning as a CDMO pioneer in the antibody-based therapeutics space.